Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.65 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 6/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782484 | 0.87 | CYP11B2 (0.85) | CYP11B2GPR55KCNJ1TSPO | |
| SCHEMBL782371 | 0.81 | CYP11B2 (0.64) | CYP11B2GPR55KCNJ1 | |
| SCHEMBL29455568 | 0.79 | CYP11B2 (0.54) | CYP11B2GPR55KCNJ1CREBBP | |
| SCHEMBL801469 | 0.78 | GPR55 (0.54) | CYP11B2GPR55KCNJ1 | |
| SCHEMBL783246 | 0.78 | CYP11B2 (0.44) | CYP11B2GPR55KCNJ1TSPOCREBBP | |
| SCHEMBL782823 | 0.77 | CYP11B2 (0.58) | CYP11B2GPR55KCNJ1 | |
| SCHEMBL10234020 | 0.76 | KCNJ1 (0.49) | CYP11B2GPR55KCNJ1TSPO | |
| SCHEMBL782587 | 0.74 | CYP11B2 (0.52) | CYP11B2GPR55KCNJ1TSPO | |
| SCHEMBL783358 | 0.74 | CYP11B2 (0.49) | CYP11B2GPR55KCNJ1 | |
| SCHEMBL782507 | 0.74 | CYP11B2 (0.48) | CYP11B2GPR55KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | CYP11B2 1/4885GPR55 852/4885KCNJ1 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.